SEC Filing Analysis: TScan Therapeutics, Inc. (TCRX)

Executive Summary

• Trading Significance: High
• Key Takeaway: CEO Gavin MacBeath was awarded 1,000,000 restricted stock units (RSUs), representing 1.53% of total shares outstanding, with vesting heavily tied to pivotal trial completion for TSC-101.
• Market Impact: Neutral to slightly positive incentive alignment, though creates potential share dilution for a micro-cap valuation.

Company Information

Field	Value
Company	TScan Therapeutics, Inc.
Ticker Symbol	TCRX
CIK	0001783328
Industry	Biological Products (No Diagnostic Substances)

Insider Information

Field	Value
Name	Gavin MacBeath
CIK	0001738082
Title/Position	Chief Executive Officer
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-10-01
Transaction Code	A (Award/Grant)
Security Type	Voting Common Stock
Shares Involved	1,000,000
Price Per Share	$0.00
Total Value	$0.00
Shares Owned After	1,049,767
Ownership Type	Direct (D)

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0.00 (Equity Grant)
% of Market Cap	~1.53% (implied equity base)
Shares Transacted	1,000,000
% of Shares Outstanding	1.53%
Post-Transaction Ownership	1,049,767 shares (1.61% of outstanding)
Materiality Assessment	Highly Significant (>0.5% of shares outstanding)

Impact Evaluation

• Market Cap Context: With TScan Therapeutics capitalized at approximately $20 million, granting 1,000,000 shares is a substantial corporate action representing roughly 1.53% of the entire company equity base.
• Ownership Concentration: Prior to this grant, CEO Gavin MacBeath held direct ownership of 49,767 shares (<0.1% of the company). The 1,000,000 RSU award dramatically elevates his stake to 1.61% post-vesting, aligning leadership interests directly with equity valuation.
• Dilution Impact: The grant introduces 1.53% potential dilution to existing shareholders upon full vesting, which is distributed across 2028 through 2030.
• Transaction Significance: Highly significant given the share volume relative to the float and the direct performance milestone attached to the vesting timeline.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: While an insider grant is not open-market buying, the performance-contingent structure ties 75% of the award directly to the completion of the TSC-101 pivotal trial, reassuring the market regarding leadership commitment to lead clinical assets.

Volume & Sentiment

• Expected Volume Impact: Low to neutral immediate volume impact, as no open-market trading took place.
• Sentiment Indicator: Neutral

Investment Insights

Positive Market Indicators

• Direct linkage of 75% of RSUs to a pivotal clinical milestone (completion of the TSC-101 trial).
• Meaningful executive skin-in-the-game increase from 49,767 shares to 1,049,767 shares.
• Multi-year retention horizon extending through September 30, 2030.

Risk Factors

• Potential 1.53% dilution of common equity in a micro-cap company.
• Grant does not represent cash outlay from insider's own capital.

Key Takeaways

1. Gavin MacBeath expanded his potential ownership position by more than twentyfold.
2. 25% of the award vests in September 2028, with the remaining 75% vesting upon completion of the TSC-101 pivotal clinical trial or September 2030.
3. The size of the grant exceeds the 0.5% threshold of outstanding shares, marking it as a structurally significant equity incentive event.

Additional Context

Transaction Notes

• Timing: Effective October 1, 2026, under the Issuer's Amended and Restated 2021 Equity Incentive Plan.
• Special Circumstances: Milestone-driven vesting structure requires continued service and clinical progress on lead oncology program TSC-101.